甲硫酸新斯的明注射液

Search documents
四家药企联合涨价被罚
Zhong Guo Xin Wen Wang· 2025-06-13 09:56
Group 1 - The State Administration for Market Regulation announced two antitrust enforcement cases in the pharmaceutical sector during a press conference on June 13, 2023 [1] - In the case involving the raw material drug Dexamethasone Sodium Phosphate, four companies collectively raised the price from 8,000 yuan per kilogram to 13,000 yuan, resulting in a total fine of 362 million yuan [1][2] - The companies involved in the price-fixing agreement included Tianjin Jiyuan Pharmaceutical Co., Zhejiang Xianju Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., and Xi'an Guokang Ruijin Pharmaceutical Co. [1] Group 2 - The Tianjin Market Regulation Commission imposed administrative penalties, including a maximum fine of 5 million yuan on individual Guo, and confiscated illegal gains from the four companies, totaling 354 million yuan [2] - Each of the four companies was fined 8% of their previous year's sales for participating in the price-fixing agreement, and four responsible individuals were fined 600,000 yuan each [2] - In March 2023, authorities also penalized companies involved in a separate case regarding the injection of Neostigmine Methylsulfate, with total fines amounting to 223 million yuan [2]
交了罚款还能挣钱?难怪药企“热衷”参与垄断
阿尔法工场研究院· 2025-05-08 14:46
Core Viewpoint - The article highlights the challenges in enforcing antitrust laws in the pharmaceutical industry, where the profits from monopolistic practices often outweigh the penalties for violations [1][5][19]. Summary by Sections Antitrust Violations and Penalties - Xianju Pharmaceutical was fined 195 million yuan for its involvement in a monopoly case concerning dexamethasone phosphate raw materials [1]. - In another case, three pharmaceutical companies colluded to raise the price of methacholine injection by 11 to 21 times, resulting in a total penalty of approximately 223 million yuan [2][5]. - The enforcement of antitrust laws in China's pharmaceutical sector has been historically lenient, with the revised Antitrust Law in 2022 introducing personal liability for executives, but actual penalties remain low compared to the profits gained from such practices [5][19]. Price Manipulation and Market Impact - The price of methacholine injection surged from 2-3 yuan to over 30 yuan per unit over a few years, before being included in a national procurement list at a price below 1 yuan [6][11]. - The sales revenue for methacholine injection exceeded 1 billion yuan in 2023, with one company holding over 69% market share [7][16]. - The article discusses how the collusion among companies not only inflated prices but also led to drug shortages, adversely affecting patients who rely on these medications [9][10]. Mechanisms of Collusion - The collusion involved explicit agreements among companies to raise prices and divide markets, which is described as a "composite monopoly agreement" [12][14]. - The article notes that such practices are not uncommon in the industry, with multiple companies engaging in similar behaviors over the years [13][14]. Enforcement Challenges - The difficulty in calculating illegal gains and the limited resources of enforcement agencies hinder effective implementation of antitrust laws [5][16]. - The penalties imposed often do not reflect the scale of the illegal profits, leading to a perception that the risks of engaging in monopolistic practices are low [15][16]. - The introduction of personal liability for executives is a step towards improving enforcement, but the effectiveness of this measure remains to be seen [18][19].
地塞米松价格操纵案发酵:三药企罚没3.26亿,“原料+制剂”垂直垄断利益链被斩断
Xin Lang Zheng Quan· 2025-05-08 02:13
Core Viewpoint - The recent antitrust penalties against three pharmaceutical companies in China highlight the exploitation of market concentration to inflate drug prices, particularly during the COVID-19 pandemic, raising concerns about unethical practices in the industry [1][7]. Group 1: Antitrust Case Details - Tianjin Municipal Market Supervision Administration imposed a total fine of 326 million yuan on Tianjin Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, and Xianju Pharmaceutical for colluding to manipulate the price of Dexamethasone Sodium Phosphate [1][7]. - The price of Dexamethasone Sodium Phosphate surged from approximately 7,900 yuan per kilogram in November 2021 to 45,000 yuan per kilogram by November 2023, indicating a significant price manipulation [1][5]. Group 2: Market Dynamics - The concentration of market competition is a key factor enabling these companies to control raw material and formulation prices, with the three companies holding four out of eight approved production licenses for Dexamethasone Sodium Phosphate [3][4]. - The demand for Dexamethasone Sodium Phosphate injections increased significantly during the pandemic, allowing companies to profit even as costs rose, leading to further price hikes [4][5]. Group 3: Regulatory Environment - The Chinese government has adopted a "zero tolerance" approach towards monopolistic behaviors in the pharmaceutical sector, as evidenced by the total fines of 1.772 billion yuan for antitrust cases in 2023 [7]. - The ongoing normalization of national medical insurance procurement and the enhancement of antitrust regulatory frameworks are expected to reduce the gray areas of vertical monopolies in the pharmaceutical industry [7].
一张罚单揭开麻醉药涨价超10倍之谜,上海医药旗下公司频被罚
Bei Ke Cai Jing· 2025-03-26 03:31
Core Viewpoint - The case involving the price manipulation of the anesthetic drug, Xinsiming Injection, reveals a significant increase in its price due to collusion among major sales companies, leading to penalties exceeding 200 million yuan for the involved parties [1][2][10]. Group 1: Price Manipulation and Market Impact - Xinsiming Injection's price surged by 11-21 times due to a collusion agreement among Shanghai Xinyi United Pharmaceutical Co., Ltd., Henan Runhong Pharmaceutical Co., Ltd., and Chengdu Huixin Pharmaceutical Co., Ltd. [1][10] - The drug, which is essential for surgeries and other medical treatments, was previously priced between 3.56-6.8 yuan per unit before the collusion, and later reached prices of 71.5 yuan, 36 yuan, and 35.8 yuan in different markets [6][7]. - The total procurement amount for Xinsiming Injection in hospitals was reported at 776 million yuan in 2021, with sales revenue for the drug reaching 511 million yuan for the same year [8]. Group 2: Regulatory Actions and Penalties - The Shanghai Municipal Market Supervision Administration imposed a total fine of 222 million yuan on the three companies involved, with Xinyi United facing the heaviest penalty of 165 million yuan [9][11]. - The case marked the first instance of individual accountability under the revised Anti-Monopoly Law, with personal fines imposed on individuals responsible for the collusion [12]. - Following the investigation, Xinsiming Injection was included in the national centralized procurement list, resulting in a significant price drop to between 0.56 yuan and 0.91 yuan per unit [14]. Group 3: Company Background and Previous Violations - Shanghai Xinyi United and its parent company, Shanghai Pharmaceuticals Holding Co., Ltd., have a history of regulatory violations, including previous penalties for accounting irregularities and price manipulation [15][17]. - The recent penalties are not expected to have a significant impact on Shanghai Pharmaceuticals' overall operations, as the affected business unit contributes less than 1% to the company's total revenue [15].